John Logan Black, M.D., explains how Mayo Clinic Laboratories'
UGT1A1 tests (Mayo IDs:
U1A1Q and
UGTFZ) identify genetic variants that increase the risk of potentially life-threatening reactions to irinotecan, a chemotherapy agent.
Speaker 3: (
00:32)
Could you give us a brief overview about your background and yourself?
Speaker 3: (
02:16)
Could you explain the role of the
UGT1A1 gene and its significance in the pharmacogenomics of irinotecan?
Speaker 3: (
05:34)
What specific tests do we offer for
UGT1A1 at Mayo Clinic Laboratories?
Speaker 3: (
08:01)
Can you clarify the difference between targeted genotyping and full gene sequencing, and when each method is most appropriate?
Could you elaborate on the specific clinical indications for testing in relation to irinotecan?
Speaker 3: (
13:27)
How do
UGT1A1 test results impact the dosing of irinotecan? What should clinicians consider when using those results?
Speaker 3: (
14:02)
Are there any other factors or related genes that should be considered alongside
UGT1A1, particularly for cancer therapy?